Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
2007

Nilotinib Treatment in Mouse Models of Lymphoblastic Leukemia

Sample size: 15 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kaur Pavinder, Feldhahn Niklas, Zhang Bin, Trageser Daniel, Müschen Markus, Pertz Veerle, Groffen John, Heisterkamp Nora

Primary Institution: Saban Research Institute, Childrens Hospital Los Angeles and the Keck School of Medicine, University of Southern California

Hypothesis

Is nilotinib effective against lymphoblastic leukemia caused by the P190 form of Bcr/Abl?

Conclusion

Nilotinib shows impressive anti-leukemia activity, but resistance can develop through mechanisms that are Bcr/Abl independent.

Supporting Evidence

  • Nilotinib-treated mice survived significantly longer than untreated mice.
  • Visible lymphoma masses disappeared within six days of treatment.
  • Nilotinib was found to be 10-25 times more effective than imatinib.

Takeaway

Nilotinib is a medicine that helps treat a type of blood cancer in mice, but sometimes the cancer can come back even after treatment.

Methodology

Mice were transplanted with leukemic cells and treated with nilotinib to assess its effectiveness in vivo.

Limitations

The study was conducted in mouse models, which may not fully replicate human responses.

Participant Demographics

C57Bl/6J mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-4598-6-67

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication